Key Highlights
- First quarter adjusted loss per share of $0.05 surpassed Wall Street’s $0.07 expectation
- After-hours trading saw SLS shares climb 20.4% following the announcement
- The company’s Phase 3 REGAL study evaluating Galinpepimut-S in AML patients has reached 78 of 80 required events for final data analysis
- Quarterly net loss expanded to $8.4 million compared to $5.8 million in the prior-year period, driven by increased R&D spending of $5.1 million
- Cash reserves stand at $107.1 million, with an additional $150 million capital raising facility established through TD Cowen
Shares of SELLAS Life Sciences (SLS) experienced a dramatic 20.4% surge during after-hours trading on Tuesday, propelled by stronger-than-anticipated first quarter financial results and a significant update regarding the company’s pivotal cancer clinical trial.
SELLAS Life Sciences Group, Inc., SLS
During the subsequent trading session, the stock maintained momentum with approximately 15% gains, according to market data.
The biotechnology company delivered an adjusted loss of $0.05 per share for the first quarter of 2026, outperforming the analyst consensus estimate of $0.07. This earnings surprise proved sufficient to capture investor enthusiasm.
The company’s net loss expanded to $8.4 million for the quarter, representing an increase from the $5.8 million loss recorded during the corresponding quarter of 2025.
Expenditure on research and development activities climbed to $5.1 million from $3.2 million on a year-over-year basis. Management explained this uptick resulted from manufacturing outlays and clinical trial activities associated with potential Biologics License Application preparation.
Operating expenses for general and administrative functions similarly rose, reaching $4.1 million versus $2.9 million in the year-ago quarter.
REGAL Trial Nearing Critical Milestone
Perhaps more significant than the earnings beat was the progress update on the REGAL clinical study. The Phase 3 investigation of Galinpepimut-S in acute myeloid leukemia patients has documented 78 events as of May 11, 2026. Only 80 total events are necessary to initiate the final data analysis.
The company maintains a blinded status regarding trial outcomes, meaning management has no visibility into the actual results at this stage.
Chief Executive Officer Angelos Stergiou described this development as “an important milestone” for SELLAS, acknowledging the dedication of trial participants, their caregivers, and the research teams involved.
Pipeline Expansion with SLS009
Beyond the REGAL program, SELLAS continues advancing SLS009, its secondary development candidate. Preclinical data unveiled at the American Association for Cancer Research conference demonstrated efficacy in AML through the inhibition of critical survival mechanisms, including activity against challenging genetic mutations such as TP53 and ASXL1.
The firm has initiated patient dosing in a Phase 2 clinical evaluation of SLS009 for newly diagnosed, first-line AML cases. This study focuses on patient populations with limited expected benefit from conventional treatment approaches, including venetoclax-based regimens.
Financial resources appear robust as these critical data milestones approach. SELLAS maintained $107.1 million in cash and cash equivalents on its balance sheet at March 31, 2026.
An additional $7.5 million in proceeds was generated during the second quarter through warrant exercise activity.
The biotechnology firm has also secured an at-the-market equity distribution agreement with TD Cowen, providing access to up to $150 million in potential capital. To date, no shares have been issued under this arrangement.
With the REGAL trial standing merely two events short of triggering its conclusive data analysis, the company’s forthcoming announcement represents the focal point for market participants.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
